argenx Buys Unnatural Products for $1.15 Billion
The Santa Cruz biotech's oral macrocyclic peptide platform will join argenx's discovery operations under a deal expected to close by year-end 2026.
Live Poll
Do you trust large drug companies to deliver better medicines when they buy smaller firms?